Dataset Information


Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.



Tumor-infiltrating CD8+ T cells are correlated with prolonged progression-free and overall survival in epithelial ovarian cancer (EOC). A significant fraction of EOC patients mount autoantibody responses to various tumor antigens, however the relationship between autoantibodies and tumor-infiltrating T cells has not been investigated in EOC or any other human cancer. We hypothesized that autoantibody and T cell responses may be correlated in EOC and directed toward the same antigens.

Methodology and principal findings

We obtained matched serum and tumor tissue from 35 patients with high-grade serous ovarian cancer. Serum samples were assessed by ELISA for autoantibodies to the common tumor antigen NY-ESO-1. Tumor tissue was examined by immunohistochemistry for expression of NY-ESO-1, various T cell markers (CD3, CD4, CD8, CD25, FoxP3, TIA-1 and Granzyme B) and other immunological markers (CD20, MHC class I and MHC class II). Lymphocytic infiltrates varied widely among tumors and included cells positive for CD3, CD8, TIA-1, CD25, FoxP3 and CD4. Twenty-six percent (9/35) of patients demonstrated serum IgG autoantibodies to NY-ESO-1, which were positively correlated with expression of NY-ESO-1 antigen by tumor cells (r = 0.57, p = 0.0004). Autoantibodies to NY-ESO-1 were associated with increased tumor-infiltrating CD8+, CD4+ and FoxP3+ cells. In an individual HLA-A2+ patient with autoantibodies to NY-ESO-1, CD8+ T cells isolated from solid tumor and ascites were reactive to NY-ESO-1 by IFN-gamma ELISPOT and MHC class I pentamer staining.

Conclusion and significance

We demonstrate that tumor-specific autoantibodies and tumor-infiltrating T cells are correlated in human cancer and can be directed against the same target antigen. This implies that autoantibodies may collaborate with tumor-infiltrating T cells to influence clinical outcomes in EOC. Furthermore, serological screening methods may prove useful for identifying clinically relevant T cell antigens for immunotherapy.


PROVIDER: S-EPMC2561074 | BioStudies | 2008-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC2867907 | BioStudies
2015-01-01 | S-EPMC4623048 | BioStudies
2013-01-01 | S-EPMC3816454 | BioStudies
1000-01-01 | S-EPMC1937553 | BioStudies
1000-01-01 | S-EPMC3326498 | BioStudies
2014-01-01 | S-EPMC3925074 | BioStudies
2020-01-01 | S-EPMC7394304 | BioStudies
| S-EPMC2835568 | BioStudies
2018-01-01 | S-EPMC6192300 | BioStudies
2019-01-01 | S-EPMC6325755 | BioStudies